论文部分内容阅读
我院于1992年2月～1994年8月应用促肝细胞生长素治疗重型肝炎取得较为满意的效果。所有病例均为住院病人，治疗组22例，对照组20例，两组病例均有消化道症状、血胆红素增高、肝功能异常、ALT增高，具有可比性。对照组采用综合基础疗法，治疗组加用促肝细胞生长素（60mg／d），1个月为1疗程。两组治疗后自觉症状消失或减退，黄疸消退;存活率治疗组高于对照组，有显著性差异（P＜0.01）;血清总胆红素（SB）与麝香草酚浊度试验（TTT）两组比较，治疗组优于对照组，有显著性差异（P＜0.01）。治疗组存活率63.63％，对照组为50％。因此，对重型肝炎的治疗在综合治疗的基础上加用促肝细胞生长素可促进病人康复，提高存活率，降低病死率。
Our hospital in February 1992 ~ August 1994 application of hepatocyte growth factor in the treatment of severe hepatitis achieved more satisfactory results. All cases were inpatients, treatment group 22 cases, control group 20 cases, two groups of patients have gastrointestinal symptoms, increased serum bilirubin, abnormal liver function, ALT increased, comparable. The control group with integrated basic therapy, the treatment group with the addition of hepatocyte growth-promoting hormone (60mg / d), 1 month for a course of treatment. There were significant differences (P <0.01) between the treatment group and the control group, the serum total bilirubin (SB) and Thymol Turbidity (TTT) The two groups, the treatment group than the control group, a significant difference (P <0.01). The survival rate of the treatment group was 63.63% and that of the control group was 50%. Therefore, the treatment of severe hepatitis in the comprehensive treatment based on the use of hepatocyte growth promoting hormone can promote patient rehabilitation, improve survival and reduce mortality.